Eli Lilly vs Viking Therapeutics: Which GLP-1 Stock Is the Better Buy?

The GLP-1 drug market is projected to reach $185 billion by 2033. Eli Lilly dominates with its successful Mounjaro and Zepbound drugs generating $13 billion in Q1 revenue, but trades at a premium 39x earnings. Viking Therapeutics, a smaller biotech with no approved products yet, offers higher risk/reward potential with its promising VK2735 candidate in phase 3 trials. The author recommends Viking as the better buy for risk-tolerant investors seeking significant upside.

06/23/2026, 10:14 AM • The Motley Fool

Set It and Forget It: 2 Consumer Stocks to Hold for the Next 20 Years

The article recommends Amazon and Costco as long-term 'set and forget' stocks suitable for 20-year holding periods. Amazon benefits from its dominance in e-commerce and cloud computing (AWS), which is experiencing explosive growth from the AI boom. Costco's membership-based model with high renewal rates (92% in U.S./Canada) and low-margin warehouse sales offset by high-margin membership fees provide stability across market conditions.

06/22/2026, 11:20 AM • The Motley Fool

Is Viking Therapeutics Stock Going to $100?

Viking Therapeutics, a biotech company developing weight loss drug candidates, could potentially reach $100 per share according to Wall Street analysts, though it currently trades around $27. The company's lead candidate VK2735, a dual GLP-1/GIP receptor agonist, is in late-stage trials and would be the first dual GLP-1/GIP drug available in oral format. Upcoming catalysts include maintenance dosing study data in Q3 and a phase 3 trial launch for the oral version in Q4. While a jump to $100 would require a 200%+ increase, positive trial results and market momentum could drive the stock higher in coming quarters.

06/12/2026, 1:15 AM • The Motley Fool

Why 1 Wall Street Analyst Thinks Viking Therapeutics Stock Could Soar 188%

A Truist Financial analyst set an $83 price target on Viking Therapeutics (VKTX), implying 188% upside from its June 8 opening price. The clinical-stage company is developing VK2735, a weight-loss drug candidate in phase 3 trials, with potential to capture a $150 billion obesity drug market by 2035. However, significant risks exist as the company has no revenue, reported a $359 million net loss in 2025, and faces trial execution risks.

06/10/2026, 1:27 PM • The Motley Fool

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

Warren Buffett and Greg Abel's Berkshire Hathaway portfolio is notably absent from the healthcare sector, holding only DaVita and recently exiting UnitedHealth Group. The article argues investors should consider healthcare independently, as it offers opportunities across multiple investment styles—from high-growth pharma/biotech plays like Eli Lilly to dividend-paying stalwarts like Johnson & Johnson and Abbott Laboratories that provide steady earnings and income.

06/03/2026, 12:05 PM • The Motley Fool

The Smartest Growth Stocks to Buy With $2,000 Right Now

The article recommends three undervalued growth stocks for investors with $2,000 to deploy: Shopify, which has declined 40% but remains the future of e-commerce; Nice Ltd, a customer service automation specialist with strong AI integration potential; and Viking Therapeutics, an emerging weight-loss drug developer with a potentially superior GLP-1 alternative in phase 3 trials.

05/30/2026, 6:15 AM • The Motley Fool

President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?

President Trump's Q1 2026 financial disclosures revealed significant purchases of Eli Lilly stock, a major player in the booming anti-obesity drug market. The article cautions investors against simply copying political trades, emphasizing that investment decisions should be based on business fundamentals rather than celebrity or political endorsements. Eli Lilly's obesity treatments Mounjaro and Zepbound generated over $30 billion in combined sales in 2025, with analysts projecting the global anti-obesity drug market could exceed $95-200 billion. While Lilly maintains a strong competitive position with manufacturing advantages and a robust pipeline, its premium valuation already reflects years of future growth, presenting significant downside risk if sales slow or competition intensifies.

05/27/2026, 2:02 PM • The Motley Fool

Prediction: These 2 Obesity Drug Stocks Could Double in 2026

The obesity drug market is projected to reach nearly $100 billion by decade's end. While Eli Lilly and Novo Nordisk dominate, two other companies—Viking Therapeutics and AbbVie—are positioned for significant growth. Viking is advancing VK-2735, a dual GLP-1/GIP receptor agonist in phase 3 trials with promising results. AbbVie is developing ABBV-295, a long-acting amylin analog with positive phase 1 data. Both stocks are predicted to potentially double in 2026 based on upcoming trial results and market expansion.

05/26/2026, 4:04 AM • The Motley Fool

Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.

Eli Lilly achieved a significant phase 3 trial win with retatrutide, a weight loss drug candidate that demonstrated superior efficacy compared to current market leaders. The drug helped patients lose an average of 28% of body weight over 80 weeks by acting on three hormonal pathways, compared to Novo Nordisk's single-pathway and Lilly's existing dual-pathway drugs. With 60% U.S. market share and this promising new candidate, Lilly is positioned to maintain dominance in the rapidly growing weight loss drug market expected to reach $100 billion by the early 2030s.

05/25/2026, 5:05 AM • The Motley Fool

Is Viking Therapeutics a Top Takeover Target?

Viking Therapeutics is increasingly viewed as an acquisition target for large pharmaceutical companies seeking obesity drug exposure. The company's lead candidate VK2735 shows strong efficacy data in both injectable and oral formulations, with Phase 3 trials underway. With a market cap of $3.6B and $603M in cash, Viking trades at $30/share while analysts project $95 price targets, making it potentially cheaper for big pharma to acquire than develop competing assets independently.

05/23/2026, 4:31 PM • The Motley Fool

2 Stocks That Could Realistically Double by 2030

Abivax and Viking Therapeutics are two biotech companies that could potentially double in value by 2030 if their leading drug candidates succeed in clinical trials and regulatory approval. Abivax is developing obefazimod for ulcerative colitis, while Viking Therapeutics is advancing VK2735 for weight loss treatment. Both stocks carry significant risk due to their clinical-stage status and lack of approved products.

05/22/2026, 3:15 AM • The Motley Fool

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics announced its participation in two major investor conferences in June 2026: the William Blair 46th Annual Growth Stock Conference (June 2-4 in Chicago) and the Jefferies Global Healthcare Conference (June 3-4 in New York). The clinical-stage biopharmaceutical company will present its pipeline including VK2735 for obesity, VK2809 for metabolic disorders, and VK0214 for rare disease treatment.

05/21/2026, 7:05 AM • Benzinga

Best Weight Loss Drug Stocks to Buy in 2026

The GLP-1 weight-loss drug market is booming with three main investment options. Eli Lilly leads with strong Mounjaro and Zepbound sales growth but trades at an expensive 35x P/E ratio. Novo Nordisk, the first-to-market player, faces pricing pressures and patent expirations but offers a compelling turnaround opportunity at a 10x P/E after a 45% stock decline. Viking Therapeutics represents a high-risk, high-reward bet for aggressive investors with GLP-1 drugs in clinical trials.

05/20/2026, 11:15 PM • The Motley Fool

Eli Lilly Stock: Next Stop $2,000?

Eli Lilly's stock has surged above $1,000 following strong Q1 results driven by its dominance in weight-loss and diabetes markets. Despite increasing competition from rivals like Novo Nordisk and Amgen, the company maintains advantages through superior pipeline candidates like Retatrutide and diversified revenue streams in oncology, immunology, and neuroscience. AI-powered drug development efforts could further accelerate growth, potentially enabling the stock to double within six years.

05/18/2026, 6:30 PM • The Motley Fool

Should Eli Lilly Investors Worry About Its Newest Rival -- From Within?

Eli Lilly dominates the rapidly growing weight loss drug market with its GLP-1 drugs Mounjaro and Zepbound, generating over $12 billion in quarterly sales. The company recently launched Foundayo, an oral GLP-1 pill, which could cannibalize Zepbound sales but is more likely to expand the patient base by attracting new GLP-1 users. While Lilly faces competition from Novo Nordisk and other pharma companies, analysts view Foundayo as a growth opportunity rather than a threat.

05/14/2026, 5:05 AM • The Motley Fool